A Trial of PEHRG214 in HIV-Infected Patients

NCT00385567 | Terminated Phase 2 DMC

• 1 other identifier: HRG2
• Study Type: interventional
• Target: 70
• Locations: 2 countries
• Sites: 7

Brief Summary

HRG2 is a Phase 2 randomized, controlled, open-label, multi-dose trial to determine the efficacy, safety, immunogenicity, and pharmacokinetic profile of PEHRG214 in HIV-infected patients, treated three times weekly for up to 16 weeks. All patients are receiving optimized standard of care HAART. The primary objective of the study is to determine the effect of PEHRG214 in decreasing the viral load (\>=1.0 log10), as compared to a Control group. The primary hypothesis is that treatment with PEHRG214 will result in clinically meaningful and sustained viral load suppression. The total sample size is 70-74 patients from approximately 8-10 participating study centers. The first 16-20 patients are enrolled in the non-randomized "pilot arm" and 54 subsequent patients are randomized (2:1 within center) to Treatment or Control group. The total study duration is 7-12 months.

Conditions

HIV Infections

Keywords

AIDS; Treatment Experienced

Outcome Measures

Primary Outcomes (3)

• Decrease in viral load >= 1.0 log10 at 16 weeks

• Positive changes in CD4 count, weight, and Karnofsky Performance Score at 16 weeks

• Improvement in quality of life as determined monthly, using the MOS-HIV Health Survey

Interventions

PEHRG214 DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Serological documentation of HIV infection at any time prior to study entry.
• CD4 cells count of \<220 cells/mm3 within 35 days of study drug administration.
• Viral load at least 10 times greater than the site laboratory's lower limit of detection within 35 days of study drug administration.
• The patient must be taking an optimized background regimen (OBR) of antiretroviral agents, as confirmed by the Principal Investigator, in accordance with the US Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, May 4, 2006; (http://www.aidsinfo.nih.gov/guidelines/) or comparable standard of care guidelines.
• OBR has been individually selected for the patient based on prior viral resistance testing and antiretroviral treatment history.
• OBR has been stable for at least 4 weeks prior to Screening and is expected to remain stable for the duration of the trial.
• Karnofsky performance status \>=60%.
• Adequate laboratory parameters: absolute neutrophil count \>1000 cells/mm3 hemoglobin \>9.0 g/dL; platelets \>75,000/mm3; creatinine \<1.5 x upper limit of normal; SGOT/SGPT \<3.0 x upper limit of normal; bilirubin \<2.0 mg/dL. Note: Patients who are taking indinavir or atazanavir will be allowed on this trial if their bilirubin is \>3.0 mg/dL and if it is deemed by both the Principal Investigator and patient's physician that the elevated bilirubin is solely related to indinavir or atazanavir.
• Women of Child Bearing Potential (WOCBP) must have a negative serum or urine pregnancy test.
• Prophylaxis for Pneumocystis carinii pneumonia using aerosolized pentamidine, trimethoprim/sulfamethoxazole, mepron or dapsone is required for study patients.
• Signed informed consent.

You may not qualify if:

• Patient is pregnant or lactating.
• Active opportunistic infection which is progressive, or imminently disabling or life-threatening, in the judgment of the Principal Investigator.
• Cytotoxic chemotherapy, interferon treatment, or radiation therapy within the preceding 3 weeks (patients who have received intralesional chemotherapy will not be excluded, however).
• Any investigational drugs within 30 days or any investigational biologic agents within 6 weeks. Patients taking antiretroviral investigational drugs within Expanded Access Programs (21CFR312.34) are not excluded from participation, provided these drugs are not excluded elsewhere in the protocol.
• Patients who have received an HIV vaccine.
• Known hypersensitivity to animal proteins, including red meats, milk, or milk products, or previous treatment with a caprine antibody and HAGAR (Human anti-goat antibody response) or the presence of HAGAR at screening.
• As this is an experimental regimen, patients will not be permitted to enroll if they had been on an effective antiretroviral regimen, which they tolerated well and which they discontinued for the sake of enrolling in this protocol.
• Active drug abuse.
• Any condition which in the Principal Investigator's opinion may render the patient unable to complete the study or which may pose significant risk to the patient.
• Chronic treatment with immunosuppressant drugs, including corticosteroids, except for the treatment of adrenal insufficiency. Topical steroids are permitted.

Sponsors & Collaborators

• Virionyx Corporation Limited: lead

Study Sites (7)

L.A. Gay & Lesbian Center

Los Angeles, California, 90028, United States

Location

University of Miami School of Medicine - AIDS Clinical Research Unit

Miami, Florida, 33136, United States

Location

Northstar Healthcare

Chicago, Illinois, 60657, United States

Location

University of Iowa - HIV/ AIDS Clinical Trials

Iowa City, Iowa, 52242, United States

Location

Beth Israel Medical Center - AIDS Clinical Trials Unit

New York, New York, 10003, United States

Location

University of Texas Southwestern Medical Center - HIV Research Clinic

Dallas, Texas, 75390, United States

Location

Clinical Research Puerto Rico, Inc

San Juan, 00909, Puerto Rico

Location

Related Publications (3)

• Verity EE, Williams LA, Haddad DN, Choy V, O'Loughlin C, Chatfield C, Saksena NK, Cunningham A, Gelder F, McPhee DA. Broad neutralization and complement-mediated lysis of HIV-1 by PEHRG214, a novel caprine anti-HIV-1 polyclonal antibody. AIDS. 2006 Feb 28;20(4):505-15. doi: 10.1097/01.aids.0000210604.78385.95.

  PMID: 16470114 BACKGROUND

• Dezube BJ, Proper J, Zhang J, Choy VJ, Weeden W, Morrissey J, Burns EM, Dixon JD, O'Loughlin C, Williams LA, Pickering PJ, Crumpacker CS, Gelder FB. A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study. J Infect Dis. 2003 Feb 1;187(3):500-3. doi: 10.1086/367710. Epub 2003 Jan 8.

  PMID: 12552435 BACKGROUND

• Pett SL, Williams LA, Day RO, Lloyd AR, Carr AD, Clezy KR, Emery S, Kaplan E, McPhee DA, McLachlan AJ, Gelder FB, Lewin SR, Liauw W, Williams KM. A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. HIV Clin Trials. 2004 Mar-Apr;5(2):91-8. doi: 10.1310/1FLN-8KFC-5HEQ-K19J.

  PMID: 15116285 BACKGROUND

MeSH Terms

Conditions

HIV Infections; Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Slow Virus Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: October 1, 2006
• First Posted: October 9, 2006
• Study Start: January 1, 2007
• Primary Completion: September 1, 2008
• Study Completion: September 1, 2008
• Last Updated: August 26, 2010

Record last verified: 2010-08

Locations

US (6); PR (1)